Q1 2022 Results slide image

Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Ophthalmology 77 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation